Passage Bio Inc Stock

$0.52

12.06% yesterday

Nasdaq, Nov 15, 10:00 pm CET

ISIN

US7027121000

Symbol

PASG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Passage Bio Inc Stock price

$0.52

-21.68 97.66% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.07 12.06%

ISIN

US7027121000

Symbol

PASG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$36.46m
Enterprise Value	$-22.55m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	0.50
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-69.34m
Cash position	$84.83m
EPS (TTM) EPS	$-1.17
P/E forward	negative
Short interest	3.19%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Passage Bio Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Passage Bio Inc forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Passage Bio Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Passage Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	2.41 2.41	38% 38% -
Gross Profit	- -	- -
- Selling and Administrative Expenses	24 24	35% 35% -
- Research and Development Expense	43 43	35% 35% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-69 -69	37% 37% -
Net Profit	-69 -69	39% 39% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Passage Bio Inc Stock News

Neutral

GlobeNewsWire

●

10 days ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.

Neutral

GlobeNewsWire

●

23 days ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)

Neutral

GlobeNewsWire

●

about 2 months ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.

More Passage Bio Inc News

Company Profile

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Head office	United States
CEO	William Chou
Employees	58
Founded	2017
Website	www.passagebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now